Project Grant R01AI189733
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University $540,818 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 6, 2025, for a five-year project concluding July 31, 2030. This Project Grant supports fundamental research investigating the interdependency of chemical, structural, and physiological heterogeneity in Pseudomonas aeruginosa biofilms. The research addresses critical gaps in...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University's Health Sciences Division a $515,387 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 11, 2025, with a completion date of July 31, 2030. This research project will investigate the mechanisms underlying how long 3' untranslated regions (3'UTRs) form in neuronal RNA and their role in triggering autoinflammatory disease....
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Trustees of Columbia University in the City of New York a Project Grant of $3.14 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, with completion targeted for January 31, 2030. The research focuses on regulatory T cell (Treg) memory in human tissues, leveraging Columbia's organ donor tissue resource for human immunology to characterize...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $246,562 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on May 26, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support basic biomedical research investigating chromatin-associated RNA processing mechanisms in early B-cell development. The research project, which extends through November 30, 2027, focuses...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University's Health Sciences Division a Project Grant of $246,750 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025 through July 31, 2027. This award supports a systematic investigation of T Follicular Helper (TFH) cells and peripheral helper T cells (TPH) across lymphoid and mucosal tissues in human subjects. The research leverages...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Colorado-Denver a Project Grant totaling $2,637,034 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 8, 2025, with a completion date of July 31, 2029. This research grant supports investigator-initiated biomedical research focused on understanding the molecular mechanisms underlying bacterial pathogenesis and intercellular spread of...
- Federal Grant Award Summary New York Medical College received a $261,846 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 2, 2025, with completion targeted for June 30, 2027. The grant supports development of an intranasal protein subunit vaccine against Pseudomonas aeruginosa (PA), a gram-negative opportunistic pathogen responsible for significant healthcare-acquired...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University a $239,135 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate a high-speed magnetics-based method for mapping the mechanical properties of tissues. The award, obligated on August 11, 2025, with a completion date of July 31, 2027, supports the creation of devices, control systems, and protocols that measure tissue...
- Federal Grant Award Summary Princeton University's Office of Research and Project Administration received a $451,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 23, 2025, with completion targeted for June 30, 2027. The research initiative employs chemical synthetic lethality methodology to identify novel antimicrobial targets in gram-negative bacterial...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Illinois a Project Grant of $736,822 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a five-year research initiative spanning February 1, 2026 through January 31, 2031. This award supports investigator-initiated research examining bacterial lipases produced by Staphylococcus aureus and their mechanisms of adaptation to the host lipid environment...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University $560,455 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 4, 2026, for a project period extending through January 31, 2031. This Project Grant supports fundamental and applied research into the assembly and function of R-bodies in Pseudomonas aeruginosa, bacterial structures that contribute to host cell damage and pathogen virulence. The research aims to elucidate the molecular mechanisms underlying R-body synthesis, toxin delivery, and host cell toxicity through investigation of the REB (R-body encoding) cluster and its constituent genes. The deliverables under this award include scientific research findings and technical outputs advancing understanding of how R-bodies function as bacterial weapons against phagocytes and other host defenses. Specifically, the research will characterize the genetic and molecular mechanisms governing R-body production and identify pathways through which associated toxins inhibit host translation and reduce host RNA levels. These research products are intended to support two overarching objectives: enabling biotechnological applications of R-bodies and identifying molecular targets for therapeutic intervention to reduce Pseudomonas aeruginosa virulence and improve treatment outcomes for chronic infections caused by this antimicrobial-resistant pathogen.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $560.5k | 2/4/26 |